The nanoparticles I am working on aggregates in physiological media and conditions. In-vivo they seem to accumulate in the liver and spleen, and not in the target site (tumor). I want to compare the hemocompatibility of the unmodified nanoparticles and the PEGylated nanoparticles. I did a in-vitro hemolysis assay using mouse blood, and found unmodified version causes 25% hemolysis.
I would now like to do some more checks to compare the hemocompatibility of the nanoparticles in-vivo.
1.Will doing activated partial thromboplastin time (APTT) or prothrombin time (PT) make any sense to my data?
2.Does nanoparticles (no heparin) administered intravenously cause activation of clotting factors by any chance?
3.What other tests can be done to check hemocompatibility in-vivo?
PT and APTT are blunted assays. For your purpose you Need ultra-specific F10a/F2a chromogenic thrombin Generation assays. Analysis of systemically circulating thrombin activity might help.
- Badges
- Science topic
- Similar topics
- Biological Science
- Zoology
- Invertebrate Zoology
- Arthropods
- Insects